Biological Times

Volume No. 3 | Issue No. 8 | Pages 30-31

Antibody-Mediated Modulation of Tumor Antigens: Mechanisms and Therapeutic Implications

Duaa Hayat*, Rais Ahmed, Hafsa Munir, Muhammad Ahsan and Irsa Mustafa

Department of Microbiology, Cholistan University of Veterinary and Animal Sciences, Bahawalpur

*Corresponding Author: **duaahayat05@gmail.com**

ABSTRACT

Antibody-mediated modulation of tumor antigens, several fresh approaches to improve the targeting of tumors as well as the effectiveness of therapies in the treatment of cancer have emerged. This article examines how antibodies may exert their effects on tumor antigens at the molecular level based on the different mechanisms. They include the use of immune system directed strategies such as the targeting of tumor recognized antigens to trigger immune responses, the use of immune system presentation pathways, and regulation of conditions in the tumor environment that would otherwise hinder immune receptor recognition. We also discuss the use of engineered antibodies to attain higher efficacy and selectivity for cancer cells including monoclonal antibodies, bispecific antibodies, and antibody drug conjugates. The applications of these approaches are therefore vast in the therapeutic sense and may offer gains in the treatment of various illnesses as well as the evolution of new treatments.

Keywords: Antigen Presentation, Tumor Antigen Heterogeneity, Targeted Therapy, Immunogenicity, Resistance Mechanisms

Introduction

Immunotherapy is a treatment approach that utilizes the body's immune system to fight neoplasms it has revolutionized the therapy of cancer(1). Of all the strategies within this field, use of antibodies to modulate tumor-associated antigens has been one of the most effective. Tumor antigens can be proteins or molecules which are located on the surface of tumor cells and are vital in the recognition of tumor cells by the immune system. However, tumors create some strategies that enable them to avoid the immune system detection and destruction, which poses a serious problem in the treatment. The other approach of antibody-mediated modulation is to use these Antibodies in order to interact with such tumor antigens, so as to modify their behavior in a way that makes them more visible to the immune system. This interaction can occur through several mechanisms the direct aiming of antigens in order to exhibit immune responses, regulation of antigen presentation channels or alteration of the tumor to enhance the possibility of immune cells interacting with tumor associated antigens. Monoclonal antibodies, bispecific antibodies and antibody-drug conjugates are engineered antibodies introduced to enhance the targets selectivity and efficacy of this strategy. This review will offer a general description of the mechanisms involved in the action of antibodies targeting tumor antigens as well as therapeutic possibilities arising from it(2). Thus, identifying these mechanisms, we aim at exploring how these strategies may be enhanced to make immunotherapies more effective and overcome the issues, including tumor antigen heterogeneity and resistance. Knowledge of these processes is critical to moving forward in the identification of specific therapies and enhancing the prospect of immunotherapy in the treatment of cancer.

Mechanisms of Antibody-Mediated Modulation

Direct Targeting of Tumor Antigens

Targeting tumor antigens through antibodies has remained more often as one of the key strategies of current immunotherapy based on antibodies that have selective affinity and activity against cancer cells. This strategy builds from the earlier understanding that certain antigens are over expressed on tumor cells as compared to normal cells, and therefore this approach is intended to deliver therapeutic value to the diseased cells while sparing healthy cells. The degree to which this strategy works is highly related to the appropriate identification of antigens that are either upregulated or solely on cancer cells(3). Such a strategy involves the direct assault of cancer cells through targeting, and monoclonal antibodies (mAbs) are its primary assets. These monoclonal reagents produced in the laboratory are aimed to have high selectivity for a given epitope on tumor antigens. The action of monoclonal antibodies resides in immunotherapy via participation of different immune processes. For example, in antibody-dependent cellular cytotoxicity (ADCC), monoclonal antibodies become attached to antigens situated on the tumor cell membrane that attracts the immune effector cells including NK cells and macrophages for destruction of the tagged tumor cells. This process occurs through the Fc part of the antibody which attaches to Fc receptors on immune cells hence eradicating the antibody coated tumor cells. The second process involves antibody-dependent cellular phagocytosis (ADCP) in which antibodies attached to tumor antigens help in the engulfing and destruction of tumor cells by macrophages. Furthermore, through receptor-mediated CDC complement activation can occur judging from the fact that monoclonal antibodies can trigger this system. Here, the antibodies bind to the tumor antigens and through the process of activating the complement they form in complex known as the membrane attack complex which in turn brings about the digestion of the tumor cells. This illustrates the possibilities of increasing the effectiveness of the therapy using monoclonal antibodies together with agents that activate complement. Bispecific antibodies and ADCs may be considered as novel trends in cancer treatment. This includes bispecific T-cell engagers (BiTEs), and Dual-affinity re-targeting (DART) proteins that are able to connect tumor cells to immune cells or recognize multiple antigens thus improving accuracy in annihilating cancer cells. ADCs conjugate antibodies with cytotoxic drugs and bound specifically to tumor cells, whereby the cytotoxic drug targets the tumor's microenvironment. The selection of the payload and linker molecules plays a significant role in the effectiveness and toxicity of ADCs. However, issues like treating tumor antigen heterogeneity, antigen loss and considerations arising from the immune responses to non-human antibodies still exist(4). Such approaches as combination therapies and constant search for new antigens are used in order to combat these problems. It predicts that therapeutic outcomes would be enhanced by accruing understanding of antibody engineering and application and launching this modality in combination with others, including checkpoint inhibitors.

Indirect Modulation via Immune System Activation

Typical immunomodulation of tumor antigens through the activation of immune response is the more elaborate approach which improves cancer treatment considering natural mechanisms of the immune system. This approach employs usage of antibodies to precipitate and encourage immune components, which in one way or another destroys tumor cells even when there is no direct interaction between the antibodies and tumor antigens. One of the ways is antibody dependent cellular cytotoxicity (ADCC). Here, antibodies fix to particular antigens exposed within tumor cells, thus attracting 'killer' immune cells such as NK cells and macrophages. The Fc region of the antibody binds to Fc receptors of these immune cells that activates the cells and brings about release of toxic compounds that destroy the tumor cells coated with the antibody(5). ADCC enhances the rate of antibody clearance of tumor cells that in turn strengthens the immune response. Another significant pathway is known as antibody-dependent cellular phagocytosis or ADCP, for short. In ADCP, antibodies coat tumor antigens where they help in opsonization of the tumor cells so that they can be engulfed by macrophages. These antibodies attach to the tumor cells and activate macrophages through Fc receptors and hence ingesting and killing the tumor cells. This process also helps in tumor destruction, activation of the immune system and improving antigen presentation to the other immune cells as well. Indirect modulation is another type which can be seen in the immune checkpoint inhibitors. These are specifically designed to inhibit immune checkpoints such as PD-1, PD L1 and CTLA 4 that are employed by tumour to avoid detection by immune cells. These therapies employ the use of antibodies that block the activity of these checkpoints which in turn improve the efficiency of T cell in recognizing and eliminating tumor cells. It enhances

To cite this article: Hayat D, R Ahmed, H Munir, M Ahsan & I Mustafa. Antibody-Mediated Modulation of Tumor Antigens: Mechanisms and Therapeutic Implications. Biological Times. 2024 August 3(8): 30-31.

the whole body's immune response toward tumor without necessarily focusing on tumor-associated antigens as shown in Fig. 1.



Fig.1: Growth of antibodies inhibited by tumor antigen.

Mechanisms of Immune Evasion and Resistance

Specifically, tumor cells employ several strategies purposefully to escape immune system detection and hence obstruct immune-antibody therapy. One of the strategies is loss or downregulation of tumor antigens expression due to genetic or epigenetic changes that can decrease the binding of antibodies to the antigens and lead to cancer relapse. Another key process relates to shifts in the systems of antigen presentation. Tumors can also inhibit the actions of antigen-presenting molecules known as major histocompatibility complex (MHC) resulting in decreased T-cell recognition. Furthermore, tumors can secrete immunosuppressive molecules such as PD-L1 that binds to T cell receptors and prevents any immune mediated tumor destruction. Another dimension of the immune evasion is the contribution of the tumor microenvironment (TME), which according to many sources, generates an immunosuppressive environment containing regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), or anti-inflammatory cytokines such as TGF-β or IL-10. This environment hampers the normals activities of immune cells in the body hence enhancing the growth of the tumor(6). In addition, tumor cells may directly suppress the immune system by secreting cytokines such as interleukin-6 (IL-6) and prostaglandin E2 (PGE2), thus changing the behavior of immune cells to support tumor survival. Immune cell invasion is also prevented by a number of TME features including the presence of a thick extracellular matrix and abnormal vasculature. Furthermore, the challenge to antibody therapies comes from antigenic drift through which tumors undergo genetic changes or epigenetic modifications causing shifts in the antigens to which the antibodies will bind. Such mechanisms need to be understood so that better strategies can be developed in the form of a combination therapy, better antibodies and modulation of TME for better cancer immunotherapy.

Therapeutic Approaches Using Antibody-Mediated Modulation

Single-clone antibodies or mAbs have greatly transformed cancer treatment since they offer selective treatment strategies. These are recombinant antibodies which are isolated from a single clone of B cell, and which are intended to have specific affinity to the tumor antigens, thus providing specific targeting of the therapy. Its potential therapeutic applications can be explained by the following several functions(7).

First of all, mAbs can cause direct elimination of tumor cells through the antibody-dependent cellular cytotoxicity (ADCC). For instance, Rituximab binds to CD20 and Trastuzumab binds to HER2 on the surface cancer cells improving the ability of immune cells to destroy tumor cells. Another strategy is the modulation of antigen presentation where mAbs inhibit proteins such as PD-1 and PD-L1 which check the immune system thus enhancing cancer cell recognition by the immune system.

Also, the development of antibody-based therapeutics helps in blocking immunosuppressive factors or the receptors required for angiogenesis, thus promoting immunological therapy and better drug administration. To successfully address complex tumor biology, mAbs can be applied together with other therapies, including checkpoint inhibitors or conventional chemotherapies.

Therefore, monoclonal antibodies possess versatile approaches to cancer antigens and enhance cancer treatment efficacies. This favorable characteristic of directly affecting the cells; the chances it has of modifying immune responses; and most importantly, the way it can be combined with other forms of treatments qualifies it as being very important in the management of cancers. The current development of new single mAbs and conjugation of two or more mAbs or other treatment modalities appears to offer hope for improving cancer therapy.

Current Challenges and Future Directions

Immunomodulation of tumor antigens through antibodies has achieved noticeable advances in cancer treatment strategies, while the following concerns should still be solved in order to improve its therapeutic effectiveness and expand its application range. Tumor antigen heterogeneity and loss also limit the effectiveness of the targeted antibodies; therefore, there should be research on targeting multiple antigens and establishing the combination of antibodies with other treatment methods such as vaccines. The tumor microenvironment (TME) is another problem since immunosuppressive cells and factors can interfere with the function of antibodies. Approaches to alter the TME could therefore enhance outcomes including the administration of antibodies with other drugs that target immunosuppressive components or immune checkpoint inhibitors(8). The issues of resistance mechanisms including antigen loss and mutations should also be addressed with a focus on the development of next generation antibodies and combinations. Off target toxicities and infusion reactions necessitate antibodies with higher specificity as well as innovative methods of administration. The two major challenges include high cost and poor availability, which highlight the importance of finding ways to bring down the cost and increasing access. Pharmacogenomics and biomarkers in the customization of treatments and the next-generation therapies, such as bispecific antibodies and ADCs, provide potential improvements. It is therefore imperative to continue with research in order to overcome these challenges in the clinical use of antibody-mediated therapies in an effort to improve the lives of those affected by cancer.

Conclusion

Immunotherapy that affects tumor antigens with the help of antibodies has greatly developed the field of cancer treatment and today is used for comprehensive treatment of a number of cancers. In the process of antibody production, the utilization of monoclonal antibodies means pointing at tumor-associated antigens more accurately and, consequently, improving patients' quality of living, as well as revealing new treatment options. However, there are still several difficulties: tumor antigen heterogeneity, immune evasion, therapeutics resistance mechanisms, inconvenient toxicity profile, and high cost, which hamper the achievement of the highest therapeutic impact and clinical translation. Further studies should be performed in relation to the eradication of such challenges with the help of the new generation of antibodies with higher selectivity and efficacy, analysis of possible options for creating a therapy based on the use of combined therapies to address the issues of antigen heterogeneity and the formation of drug resistance, and the enhancement of the safety of treatments. Further, advancements in antibody engineering and personalized medicine have the potential to bring benefits to increase the efficiency of antibody therapies. Addressing these issues and advancing further, we thus conceive that antibody-mediated modulation will grow to be capable of delivering better and affordable cancer management that consequently enhances patient survival and therapeutic value across different cancer subtypes.

References

[1] Sahu M, Suryawanshi H. Immunotherapy: The future of cancer treatment. Journal of Oral and Maxillofacial Pathology. 2021;25(2):371.
[2] Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nature reviews cancer. 2012;12(4):278-87.
[3] Coulie PG, Van den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer. 2014;14(2):135-46.
[4] van Schie KA, Wolbink G-J, Rispens T, editors. Cross-reactive and pre-existing antibodies to therapeutic antibodies—effects on treatment and immunogenicity. MAbs; 2015: Taylor & Francis.
[5] Janeway Jr CA, Travers P, Walport M, Shlomchik MJ. The destruction of antibody-coated pathogens via Fc receptors. Immunobiology: The Immune System in Health and Disease 5th edition: Garland Science; 2001.
[6] Peña-Romero AC, Orenes-Piñero E. Dual effect of immune cells within tumour microenvironment: pro-and anti-tumour effects and their triggers. Cancers. 2022;14(7):1681.
[7] Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews Drug discovery. 2010;9(8):615-27.
[8] Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal transduction and targeted therapy. 2021;6(1):72.